deutsch english

Antibodies for Licensing

Scientists at the Georg-August-University Göttingen generated many different monoclonal antibodies. We are looking for companies, who are interested in licensing these antibodies for selling them to industrial and scientific institutions or for developing advanced diagnostic tests and therapeutic solutions.
This unique collection comprises the listed clones:

Overview available clones for licensing

Name Clones Host Reactivity Isotype Application References
Complementfactor B / Ba P21/15 mouse human IgG2a/k WB,E,IP 1-3
  M20/6 mouse human IgG1/k WB,E,IP 1-4
  D22/3 mouse human IgG2b/k WB,F,E 2-4
Complementfactor B / Bb M13/12 mouse human IgG1/k WB,E,IP 1-3
Complementfactor D D10/4 mouse human IgG2a/k WB,E 1-3; 5
  I8/1 mouse human IgG1/k WB,E 1-3; 5
Complementfactor H C18/3 mouse human IgG1/k WB,E 1-3
  L20/3 mouse human Ig1/k WB,E 1-3
Complementfactor H (402-His variant) IH10 mouse hunman lgG1/k IB, ELISA not yet published
Complementfactor H (402-Tyr variant) 23F8 mouse human lgG1/k IB, ELISA not yet published
Activated C3 (iC3b/C3dg) I3/15 mouse human Ig1/k WB,E 1-3; 6; 7
C3a/C3a(desArg)/C3 K13/16 mouse human IgG1/k WB,E,IP,FN 2; 3; 8-16
  D17/1 mouse human IgG1/k WB,E 2; 3; 8; 10; 14-16
C5a/C5a(desArg)/C5 C17/5 mouse human IgG1/k WB,E 2; 3; 8; 10: 14-16; 19
  G25/2 mouse human IgG1/k WB,E 2; 3; 8; 10: 14-16; 19
C3a/C3a(desArg) Z22/8 mouse porcine IgG2b/k WB,E,IP,FN 3; 17;18
  K5/9 mouse porcine IgG1/k WB, E,FN 3; 17;18
C5a/C5a (desArg) T13/9 mouse porcine IgG1/k WB,E,IP,FN 3; 17;18
Complementreceptor C5aR (CD88) P12/1 mouse human IgG1/k WB, F, IH 20
  S5/1 mouse human IgG2a/k WB, F, E, FN, IP, blocking 20
  W17/1 mouse human IgG1/k F,E 20
  R63 mouse rat IgG1/k F,IH 21
Phospho-C5aR/CD88 (Ser-334) 32G-1 mouse human lgG1/k WB, IF, E20 42
Chemokine receptor CCR5 R22/7 mouse human   IF, FC, WB 22
  T21/8 mouse human   IF, FC, WB, IP, E 22
Phospho CCR5 (Ser-349) E11/19 mouse human   IF, WB, E 22
Phospho CCR5 (Ser-337) V14/2 mouse human   I, WB, E 22
Nonphospho-CCR5 (Ser 337) RC-10 mouse human   IF, WB, E 22
  R22/7 mouse human   IF, FC,WB 22
Chemokine receptor CCR7 4B12 rat mouse IgG2a IP, F 23; 24
Complementreceptor C3aR hC3aRZ8 (clone17 mouse human IgG2b F, IH 25; 26
  hC3aRZ3 (clone76 mouse human IgG2b FI 27;28
  74 mouse rat   F, IH 29
  IG4 rat mouse IgG1/k F, IH 26
  14D4 rat mouse IgG2a F, IH 26
Complementreceptor C5aR 20/70 rat mouse IgG2b F, Blocking 30;31;32
  10/92 rat mouse IgG2a F, IH 31
  8D6 rat human IgG2a F, IH, Blocking not yet published
  15C4 rat human IgG2a F, IH, Blocking not yet publishhed
Beta-arrestin1 and Beta-arrestin2 25G10 mouse human, rat,hamster beta-arrestin1 IgG1/k WB, IP not yet published
  21B1 mouse human, rat, hamster beta-arrestin1 and beta-arrestin2 Ig1/k WB, IP 44
Chemokine receptor CCR9 9B1 rat mouse IgG2a/k F 33
Interleukin 8 SE2 mouse human IgG2b/k F, WB, IH 34
  HC2 mouse human IgG1/k F, WB IH 34
Complementfactor H IH10 mouse human IgG1/k IB, ELISA not yet published
  23F8 mouse human IgG1/k IB, ELISA not yet published
Beta2-adrenergic receptor 13D6 mouse human IgG1/k IB, IP, IF, F not yet published
  R11E1 mouse human IgG1/k IB, IP, IF, F 43
PIWIL2 87/3 mouse human lgM IH, ELISA not yet published
Pox Viruses BCoV1/1 mouse bovine coronavirus; human coronavirus lgG1 E; IF; VN 35
  FPXV-8F3 mouse Fowlpoxvirus, Turkeypoxvirus IgG3/k E, IF, IB, IP, IGEM, NVN 36
  FPXV-3D9 mouse Fowlpoxvirus, Turkeypoxvirus IgG1 E, IF, IB, IP, IGEM, NVN 36;37
  VACV-5B4 mouse All orthopoxviruses without ectomelia and monkeypox IgG2a E, IF, IB, IP, F, IGEM, VN 38;39;40
  VACV-5C7 mouse Monkeypoyvirus and other orthopoxviruses IgG1 E, IF, IB, IP, IGEM, NVN 39
  PPV-4D9 mouse All Parapoxviruses IgM E, IF, IB, IP, F, IGEM, VN 41
  CNPV-5A11 mouse Canarypox virus IgG2a/k E, IF, IB, IP, IGEM, NVN 37
  VACV-5B1 mouse All orthopoxviruses IgG2a E, IF, IB, IP, F, IGEM, NVN 39
AP-Tag / Avitag EF10 mouse human IgG1/k E, IF, F, FN 45

E: ELISA; IF: Immunofluorescence; IB: Immunoblotting; IP: Immunoprecipitation; IGEM: Immunogold electron microscopy; IH: Immunohistochemistry; F: Flow cytometry; FN: Functional studies; NVN: not virus neutralizing; VN: virus neutralizing; WB: Western blotting

Reference List for monoclonal antibodies mAB

  1. Oppermann, M., Baumgarten, H., Brandt, E., Gottsleben, W., Kurts, C., and Götze, O. (1990) J. Immunol.Methods133, 181-1902.    
  2. Oppermann, M., Kurts, C., Zierz, R., Quentin, E., Weber, M. H., and Götze, O. (1991) Kidney Int.40, 939-947.
  3. Oppermann, M., Höpken, U., and Götze, O. (1992) Immunopharm.24, 119-134 
  4. Oppermann, M. and Götze, O. (1994) Mol. Immunol.31, 307-314
  5. Kaiser, J., Oppermann, M., Götze, O., Deppisch, R., Göhl, H., Asmus, G., Röhrich, B., von Herrath, D., and Schäfer, K. (1994) Significant reduction of factor D and immunosuppressive complement fragment Ba by  haemofiltration. 
  6. Würzner, R., Schuff-Werner, P., Franzke, A., Nitze, R.,Oppermann, M., Armstrong, V. W., Eisenhauer, T., Seidel, D., and Götze, O. (1991) Eur. J. Clin. Invest.21, 288-294. 
  7. Schuff-Werner, P., Schütz, E., Reitemeyer, F., Oppermann, M., Eisenhauer, T., Armstrong, V., Köstering, H., Götze, O., and Seidel, D. (1990) Heparin-induced extracorporeal LDL-precipitation (HELP): rheological, hemostaseological and immunological effects. In Gotto, A. M., Mancini, M., Richter, W. O., and Schwandt, P., editors. Treatment of severe hypercholesterolemia in the prevention of coronary heart disease, Basel, Karger
  8. Oppermann, M., Haubitz, M., Quentin, E., and Götze, O. (1988) Klin. Wochenschr.66, 857-864 
  9. Püschel, G. P., Oppermann, M., Muschol, W., Götze, O., and Jungermann, K. (1989) FEBS Lett.243, 83-87 
  10. Nezlin, R., Freywald, A., and Oppermann, M. (1993) Mol. Immunol.30, 935-940
  11. Püschel, G. P., Hespeling, U., Oppermann, M., and Dieter, P. (1993) Hepatology18, 1516-1521
  12. Elsner, J., Oppermann, M., Czech, W., Dobos, G., Schöpf, E., Norgauer, J., and Kapp, A. (1994) C3a activates oxygen radical species production and intracellular calcium transients in human eosinophils. 
  13. Elsner, J., Oppermann, M., Czech, W., Schöpf, E., and Kapp, A. (1994) Blood83, 3324-3331.
  14. Ammon, H. P. T., Ege, W., Oppermann, M., Göpel, W., and Eisele, S. (1995) Anal. Chem.67, 466-471
  15. Püschel, G. P., Dieter, P., Muschol, W., Oppermann, M., Hülsmann, M., Schulze-Specking, A., Götze, O., Decker, K., and Jungermann, K. (1991) Prostanoid production in Kupffer cells: A step in the increase in glucose and lactate output and reduction of flow by anaphylatoxins in perfused rat liver. In Wisse, E., Knook, D. L., and Decker, K., editors. Cells of the hepatic sinusoid, Leiden, Kupffer Cell Foundation 
  16. Lhotta, K., Würzner, R., Kronenberg, F., Oppermann, M., and Konig, P. (1998) Kidney Int.53, 1044-1051
  17. Höpken, U., Strüber, A., Oppermann, M., Mohr, M., Mücke, K. H., Burchardi, H., and Götze, O. (1993), Production and characterization of peptide-specific monoclonal antibodies that recognize a neoepitope on hog C5a. In Faist, E., Meakins,  J., and Schildberg, F. W., editors. Host  defense dysfunction in trauma, shock and sepsis, Berlin, Heidelberg, Springer Verlag.
  18. Höpken, U., Mohr, M., Struber, A., Montz, H., Burchardi, H., Götze, O., and Oppermann, M. (1996) Eur. J. Immunol.26, 1103-1109
  19. Oppermann, M., Schulze, M., Götze, O. (1991) A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using monoclonal antibody with specificity for a neotope. Complement Inflamm. 8 (1):13-24
  20. Oppermann et al, J.Immunol. 1993, 151:3785-95
  21. Schlaf et al, Lab Invest.79:1287-97
  22. Pollok-Kopp, B. et al., J. Biol. Chem. 2003 278:2190
  23. Ohl, L. et al., (2004) Immunity21:279-88
  24. Ritter, U. Et al., (2004) J. Leukoc Biol., 76:472-476
  25. Soruri, A., Kiafard, Z., Dettmer, C., Riggert, J., Kohl, J., Zwirner, J., (2003), IL-4 down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo. J. Immunol. 170:3306–3314
  26. Kiafard, Z., Tschernig, T., Schweyer, S., Bley, A., Neumannd, D., Zwirner, J., (2007), Use of monoclonal  antibodies to assess expression of anaphylatoxin receptors in tubular epithelial cells of human, murine and rat kidneys. Immunobiology, 212:129–139
  27. Werfel, T., Kirchhoff K, Wittmann M, Begemann G, Kapp A, Heidenreich F, Götze O, Zwirner J., (2000) J     Immunol., 165:6599-605.
  28. Zwirner, J., Götze O, Begemann G, Kapp A, Kirchhoff K, Werfel T., (1999),  Immunology., 97:166-72
  29. Luhmann, A.E., et al., 2001, Mol Immunol, 38: 108 (Abstract)
  30. Godau, J. Et al., (2004), J of Immunol., 173(5): 3437-45
  31. Soruri, A. et al., (2003), 88: 47-52
  32. Shushakova, N. et al, (2002), Journal Clin Invest, 110: 1823-30
  33. Rivera-Nieves J, Ho J, Bamias G, Ivashkina N, Ley K, Oppermann M, Cominelli F. (2006), Gastroenterology. 131 (5):1518-29
  34. Zahn, S., Zwirner, J., Spengler, H.P., Götze, O. (1997), Eur J Immunol,27(4): 935-40
  35. Czerny, C.-P., Eichhorn, W. (1989): Characterization of monoclonal and polyclonal antibodies to bovine enteric coronavirus, establishment of an efficient ELISA for antigen detection in feces. Vet.Microbiol.20: 111-122
  36. Boulanger, D., Green, Smith, T., Czerny, C.-P., Skinner, M.A. (1998): The 131-amino-acid repeat region of the essential 39-kilodalton core protein of fowlpox virus FP9, equivalent to vaccinia virus A4L protein, is non-essential and highly immunogenic.  J.Virol.72: 170-179
  37. Isa, G., Pfister, K., Kaaden, O.-R., Czerny, C.-P. (2002): Development of a monoclonal blocking ELISA for the detection of  antibodies against fowlpox virus. J.Vet.Med.B.49: 21-23.
  38. Czerny, C.-P., Mahnel, H. (1990): Structual und functional analysis of orthopox virus epitopes. J.Gen.Virol., 71:  2341-2352.
  39. Czerny, C.-P., Johann, S., Hölzle, H., Meyer, H. (1994): Epitope detection in the envelope of intracellular naked  orthopox viruses and identification of their encoding genes. Virology200: 764-777.
  40. Meyer, H., Osterrieder, N., Czerny, C.-P. (1994): Identification of binding sites for neutralizing monoclonal antibodies on the 14 kDa fusion protein of different orthopox virus species. Virology200: 778-783.
  41. Czerny, C.-P., Waldmann, R., Scheubeck, T. (1997): Identification of three different antigenic sites in parapox viruses. Arch.Virol.142: 807-821.
  42. Pollok-Kopp B., Hüttenrauch, F., Rethorn, S., Oppermann, M.,  J. Biol. Chem. (2007) 282:4345
  43. Huang, C. et al. J. Biol. Chem. (2009) 284:17206
  44. Hüttenrauch, F. et. al. (2005) J. Biol. Chem. 280:37503
  45. Liebick M., Schläger C., Oppermann M. (2016) Analysis of Chemokine Receptor Trafficking by Site-Specific Biotinylation. PLOSOne11 (6):e0157502.

Contact

Dipl.-Biol. Christiane Bolli
Licensing Manager Research Materials
E-Mail: cbolli(at)sciencebridge.de
Tel.: +49 551 30724 156

Download als PDF
Die Fusszeile

Eine Tochter der